Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYANOTECH CORPCYAN · Entity 8431 | Director | October 18, 2021 | October 20, 2021 |
| NeuroMetrix, Inc.NURO · Entity 14008 | Director | May 01, 2025 | May 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYANOTECH CORP
Report date October 18, 2021 · Filed October 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Cyanotech Corporation Common StockSEC Table I · non-derivative | Direct | 55,395 |
Reported balance
After 2021-10-18 transaction · row 1
1 source rowRow 1 · 2021-10-18 · Grant · Acquired 11,228 · Balance 55,395 |
NeuroMetrix, Inc.
Report date May 01, 2025 · Filed May 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-01 transaction · row 1
1 source rowRow 1 · 2025-05-01 · Disposition to issuer · Disposed 7,602 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated December 17, 2024 (the "Merger Agreement"), by and among the Issuer, electroCore, Inc., a Delaware corporation ("Parent"), and Nexus Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). F2: Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.0001 per share, of the Issuer that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount in cash (the "Per Share Cash Consideration') equal to a pro rata share of the Company's balance of net cash at the Effective Time, after deduction of certain pro rata payments made accordance with the Issuer's Amended and Restated Management Retention and Incentive Plan, without interest and (ii) one contingent value right (a "CVR") representing the right to receive contingent payments subject to the terms and conditions set forth in a contingent value rights agreement entered into between Parent and Equiniti Trust Company, LLC. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-01 · Disposition to issuer · Disposed 13,730 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) the Per Share Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated December 17, 2024 (the "Merger Agreement"), by and among the Issuer, electroCore, Inc., a Delaware corporation ("Parent"), and Nexus Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub").
F2: Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.0001 per share, of the Issuer that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount in cash (the "Per Share Cash Consideration') equal to a pro rata share of the Company's balance of net cash at the Effective Time, after deduction of certain pro rata payments made accordance with the Issuer's Amended and Restated Management Retention and Incentive Plan, without interest and (ii) one contingent value right (a "CVR") representing the right to receive contingent payments subject to the terms and conditions set forth in a contingent value rights agreement entered into between Parent and Equiniti Trust Company, LLC.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) the Per Share Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2025 Filed May 5, 2025 17:52 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | Disposition to issuerRestricted Stock Unit · Derivative | 13,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-008730 · ownership.xml · derivative · entry 2 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,730 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) the Per Share Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such RSUs. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) the Per Share Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such RSUs. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) the Per Share Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such RSUs. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) the Per Share Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such RSUs. Read SEC document |
| May 01, 2025 Filed May 5, 2025 17:52 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | Disposition to issuerCommon Stock | 7,602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-008730 · ownership.xml · nonDerivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated December 17, 2024 (the "Merger Agreement"), by and among the Issuer, electroCore, Inc., a Delaware corporation ("Parent"), and Nexus Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). F2 · shares: Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.0001 per share, of the Issuer that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount in cash (the "Per Share Cash Consideration') equal to a pro rata share of the Company's balance of net cash at the Effective Time, after deduction of certain pro rata payments made accordance with the Issuer's Amended and Restated Management Retention and Incentive Plan, without interest and (ii) one contingent value right (a "CVR") representing the right to receive contingent payments subject to the terms and conditions set forth in a contingent value rights agreement entered into between Parent and Equiniti Trust Company, LLC. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated December 17, 2024 (the "Merger Agreement"), by and among the Issuer, electroCore, Inc., a Delaware corporation ("Parent"), and Nexus Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). F2 · price: Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.0001 per share, of the Issuer that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount in cash (the "Per Share Cash Consideration') equal to a pro rata share of the Company's balance of net cash at the Effective Time, after deduction of certain pro rata payments made accordance with the Issuer's Amended and Restated Management Retention and Incentive Plan, without interest and (ii) one contingent value right (a "CVR") representing the right to receive contingent payments subject to the terms and conditions set forth in a contingent value rights agreement entered into between Parent and Equiniti Trust Company, LLC. Read SEC document |
| May 22, 2024 Filed May 24, 2024 17:12 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | GrantRestricted Stock Unit · Derivative | 13,730 | $4.37 Strike: $4.37 | $60,000.10 |
DisclosureSEC source: 0001628280-24-025264 · wk-form4_1716585163.xml · derivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,730 Underlying: Common Stock · 13,730 shares Expires 2025-04-29 F1 · shares: On May 22, 2024, the reporting person was granted 13,730 restricted stock units with 100% vesting to occur on the earlier of the date of the 2025 annual meeting of stockholders or a change in control of the Issuer, subject to the Reporting Person's continued service on the Board of Directors on such date. F2 · price: Pricing on the Nasdaq market on April 30, 2024. Read SEC document |
| April 30, 2024 Filed May 2, 2024 16:00 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | Exercise / conversionRestricted Stock Unit · Derivative | 5,396 | $4.37 Strike: $4.37 | $23,580.52 |
DisclosureSEC source: 0001628280-24-019975 · wk-form4_1714680032.xml · derivative · entry 2 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,396 shares Expires 2024-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On August 4, 2023, the reporting person was granted 43,165 restricted stock units prior to the reverse stock split of the Issuer's common stock at a ratio 1-for-8, effective as of November 21, 2023, which vested 100% on April 30, 2024. Read SEC document |
| April 30, 2024 Filed May 2, 2024 16:00 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | Exercise / conversionCommon Stock | 5,396 | $4.37 | $23,580.52 |
DisclosureSEC source: 0001628280-24-019975 · wk-form4_1714680032.xml · nonDerivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares earned upon the vesting of restricted stock units referred to in footnote 2. Read SEC document |
| August 04, 2023 Filed Aug 4, 2023 18:17 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | GrantRestricted Stock Unit · Derivative | 43,165 | $1.39 Strike: $1.39 | $59,999.35 |
DisclosureSEC source: 0001628280-23-027595 · wk-form4_1691187451.xml · derivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,165 Underlying: Common Stock · 43,165 shares Expires 2024-04-30 F2 · price: Nasdaq closing price on May 2, 2023, the date of the Board of Directors approval. F1 · derivative.exercise_date: 100% vesting on April 30, 2024 Read SEC document |
| May 02, 2023 Filed May 5, 2023 16:35 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | Exercise / conversionRestricted Stock Unit · Derivative | 17,647 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001628280-23-016168 · wf-form4_168331890172901.xml · derivative · entry 2 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,647 shares Expires 2023-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 5, 2023 16:35 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | Exercise / conversionCommon Stock | 17,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-016168 · wf-form4_168331890172901.xml · nonDerivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2022 Filed May 26, 2022 15:27 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | GrantRestricted Stock Unit · Derivative | 17,647 | $3.40 Strike: $3.40 | $59,999.80 |
DisclosureSEC source: 0001628280-22-015462 · wf-form4_165359326146336.xml · derivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,647 Underlying: Common Stock · 17,647 shares Expires 2023-05-02 F1 · derivative.exercise_price: Nasdaq closing price on May 3, 2022, the date of Board of Directors approval. F2 · date: Grants were approved by the Company's Board of Directors on May 3, 2022 but were not issued until May 24, 2022 after the Company had filed a registration statement on Form S-8 to register the increase in capacity under its equity plans that was approved at the Company's Annual Shareholder Meeting held on May 3, 2022. F3 · derivative.exercise_date: 100% vesting on May 2, 2023 Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 16:15 UTC | CYANOTECH CORP CYAN · Entity 8431 | GrantCyanotech Corporation Common Stock | 11,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-023969 · rdgdoc.xml · nonDerivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,395 Read SEC document |
| May 27, 2021 Filed Jun 4, 2021 16:55 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | GrantStock Option (right to buy Common Stock) · Derivative | 5,000 | $2.92 Strike: $2.92 | $14,600.00 |
DisclosureSEC source: 0001628280-21-011689 · wf-form4_162284009483453.xml · derivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,692 Underlying: Common Stock · 5,000 shares Expires 2031-05-27 F1 · derivative.exercise_date: This option vests as follows, 25% on May 27, 2022 and 1/16th each quarter thereafter. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 15:15 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | GrantStock Option (right to buy Common Stock) · Derivative | 5,000 | $3.08 Strike: $3.08 | $15,400.00 |
DisclosureSEC source: 0001628280-21-000484 · wf-form4_161074173595926.xml · derivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,692 Underlying: Common Stock · 5,000 shares Expires 2031-01-12 F1 · derivative.exercise_date: This option vests as follows: 25% on January 12, 2022 and 1/16th each quarter thereafter. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 15:41 UTC | CYANOTECH CORP CYAN · Entity 8431 | GrantCyanotech Corporation Common Stock | 13,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-019014 · rdgdoc.xml · nonDerivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,167 Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:55 UTC | CYANOTECH CORP CYAN · Entity 8431 | GrantCyanotech Corporation Common Stock | 15,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-003203 · rdgdoc.xml · nonDerivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,722 Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 17:32 UTC | CYANOTECH CORP CYAN · Entity 8431 | GrantCyanotech Corporation Common Stock | 8,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-016358 · rdgdoc.xml · nonDerivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,556 Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:55 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | GrantStock Option (right to buy Common Stock) · Derivative | 5,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001628280-18-005731 · wf-form4_152529454145265.xml · derivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,971 Underlying: Common Stock · 5,000 shares Expires 2028-05-01 F1 · derivative.exercise_date: This option vests as follows: 25% on May 1, 2019, and 1/16 each quarter thereafter Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 16:08 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | GrantStock Option (right to buy Common Stock) · Derivative | 10,000 | $1.78 Strike: $1.78 | $17,800.00 |
DisclosureSEC source: 0001628280-18-000669 · wf-form4_151726006733906.xml · derivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,971 Underlying: Common Stock · 10,000 shares Expires 2021-01-25 Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 16:18 UTC | CYANOTECH CORP CYAN · Entity 8431 | GrantCyanotech Corporation Common Stock | 6,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-015324 · rdgdoc.xml · nonDerivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,809 Read SEC document |
| August 24, 2017 Filed Oct 31, 2017 14:47 UTC Amendment | CYANOTECH CORP CYAN · Entity 8431 | GrantCyanotech Corporation Common Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-017942 · rdgdoc.xml · nonDerivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 F1 · shares: Due to a clerical error, the number of shares acquired was previously misreported as 6,809 shares in the reporting person's Form 4 filed on August 25, 2017. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 17:03 UTC | NeuroMetrix, Inc. NURO · Entity 14008 | GrantCommon Stock · Derivative | 1,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001628280-17-008235 · wf-form4_150213981293703.xml · derivative · entry 1 KATZ NANCY E · CIK 0001189692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,971 Underlying: Common Stock · 1,000 shares Expires 2027-08-03 F1 · derivative.exercise_date: This option vests as follows: 25% on August 3, 2018, and 1/16 each quarter thereafter Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.